EXAMPLE OF AN OVARIAN NEOPLASM USING PROPOSED TEMPLATE

- Case: High-grade serous carcinoma of right ovary primary
  - Total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, regional lymphadenectomy (pelvic and para-aortic lymph nodes), multiple peritoneal biopsies, removal of portion of small intestine
  - Tumor measures 9.0 x 8.3 x 6.6 cm
  - Tumor involves right ovary (surface+), right fallopian tube, uterine serosa, omentum (omental cake), 1 (of 11) pelvic lymph nodes, 0 (of 4) para-aortic lymph nodes, right cul-de-sac, small intestine serosa
  - Negative LVI
  - Positive cytology
  - Hormone receptors: ER positive (50%, variable), PR positive (10%, variable)

OVARIAN NEOPLASM

1. Specimen(s): Uterus, cervix, bilateral fallopian tubes, bilateral ovaries, omentum, peritoneal biopsies (as specified in gross), portion of small intestine
2. Procedure(s): Total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, peritoneal biopsies, segmental excision of small intestine, regional lymphadenectomy (as specified)
3. Regional Lymph Node Sampling: Performed
4. Specimen Integrity: Intact
5. Primary Tumor Site: Right ovary
6. Tumor Size:
   a. Greatest dimension: 9.0 cm
   b. Total dimensions: 9.0 x 8.3 x 6.6 cm
7. Histologic Type: High-grade serous carcinoma
8. Histologic Grade: High-grade
9. Ovarian Stromal Invasion: Present
10. Lymph-Vascular Space Invasion: Absent
11. Serosal Surface Involvement: Present; right ovary
12. Implants/Other Sites Involved: Present; uterine serosa, omentum, right cul-de-sac, small intestine serosa
13. Regional Lymph Nodes: Positive; 1/15; extranodal extension absent
15. Hormone Receptor Expression (by immunohistochemistry):
   a. ER: Positive; 50%, variable
   b. PR: Positive; 10%, variable
16. Mismatch Repair (MMR) Protein Expression (by immunohistochemistry):
   a. Not performed
17. Pathologic Staging: AJCC [pT3c N1]; FIGO [IIIC]

OVARIAN NEOPLASM TEMPLATE (specific details to be added into SOFT)

1. Specimen(s): list all specimens removed during case
2. **Procedure(s): select all that apply**
   a. [Total abdominal hysterectomy]
   b. [Radical hysterectomy]
   c. [Supracervical hysterectomy]
   d. [Bilateral salpingo-oophorectomy]
   e. [Bilateral oophorectomy]
   f. [Bilateral salpingectomy]
   g. [Right salpingo-oophorectomy]
   h. [Right oophorectomy]
   i. [Right salpingectomy]
   j. [Left salpingo-oophorectomy]
   k. [Left oophorectomy]
   l. [Left salpingectomy]
   m. [Omentectomy]
   n. [Peritoneal biopsies]
   o. [Peritoneal washings]
   p. [Other, <SPECIFY>]

3. **Regional Lymph Node Sampling: select whether or not lymph nodes were removed**
   a. [Performed]
   b. [Not performed]
   c. [Not applicable]
   d. [Cannot be determined]

4. **Specimen Integrity: document whether intact or received fragmented. This absolutely requires correlation with the operative report**

5. **Primary Tumor Site: select all that apply**
   a. [Right ovary]
   b. [Left ovary]
   c. [Bilateral ovaries]
   d. [Cannot be determined]

6. **Tumor Size: provide greatest dimension and total dimensions, if both ovaries equally involved, list separately**
   a. [Greatest dimension: <SPECIFY>]
   b. [Total dimensions: <SPECIFY>]
   c. [Cannot be determined]

7. **Histologic Type: select appropriate tumor type**
   a. [Atypical proliferative/borderline serous tumor]
   b. [Atypical proliferative/borderline serous tumor with micropapillary features]
   c. [Atypical proliferative/borderline serous tumor with cribriform features]
   d. [Atypical proliferative/borderline seromucinous tumor (“mixed epithelial tumor”, “endocervical type mucinous tumor”)]
   e. [Atypical proliferative/borderline mucinous tumor, gastrointestinal type]
f. [Atypical proliferative/borderline endometrioid tumor]
g. [Atypical proliferative/borderline clear cell tumor]
h. [Atypical proliferative/borderline Brenner tumor]
i. [Low-grade serous carcinoma]
j. [High-grade serous carcinoma] (use of the term “papillary” is not recommended)
k. [Mucinous carcinoma, gastrointestinal type]
l. [Endometrioid carcinoma]
m. [Clear cell carcinoma]
n. [Malignant Brenner tumor]
o. [Transitional carcinoma]
p. [Undifferentiated carcinoma]
q. [Carcinosarcoma (malignant mixed Mullerian tumor, MMMT)]
r. [Small cell carcinoma, hypercalcemic-type (“malignant rhabdoid tumor of the ovary”)]
s. [Mixed carcinoma <SPECIFY TYPES AND APPROXIMATE PERCENTAGES>]
t. [Adult-type granulosa cell tumor]
u. [Juvenile granulosa cell tumor]
v. [Sertoli-Leydig cell tumor]
w. [Sex cord tumor with annular tubules (SCTAT)]
x. [Steroid cell tumor, not-otherwise-specified]
y. [Other sex cord-stromal tumor <SPECIFY>]
z. [Dysgerminoma]
aa. [Embryonal carcinoma]
bb. [Yolk sac tumor]
cc. [Choriocarcinoma]
dd. [Immature teratoma]
ee. [Carcinoma ex teratoma]
ff. [Malignant mixed germ cell tumor <SPECIFY TYPES AND APPROXIMATE PERCENTAGES>]
gg. [Other, <SPECIFY>]

8. Histologic Grade: <SPECIFY GRADE OF TUMOR> (grading system will depend on tumor type)

9. Ovarian Stromal Invasion:
   a. [Absent]
   b. [Present; microinvasion (< 0.5 cm)] (for use in borderline tumors)
   c. [Present; > 0.5 cm] (for use in borderline tumors)
   d. [Present] (for use in high-grade tumors where amount of stromal invasion doesn’t matter)

10. Lymph-Vascular Space Invasion: state whether LVI is present
    a. [Absent]
    b. [Present]
    c. [Suspicious]
    d. [Cannot be determined]

11. Ovarian Surface Involvement: specify whether there is surface involvement
12. **Implants/Other Sites Involved:** state whether there is disease outside the primary
   a. [Negative]
   b. [Positive: <LIST OTHER ORGANS INVOLVED> ; <PROVIDE SIZE OF LARGEST METASTATIC FOCUS> (high-grade tumors)]
   c. [Non-invasive implants: <LIST NON-INVASIVE IMPLANT SITES>] (borderline and low-grade tumors)
   d. [Invasive implants: <LIST INVASIVE IMPLANT SITES> ; <PROVIDE SIZE OF LARGEST METASTATIC FOCUS>] (borderline and low-grade tumors)

13. **Regional Lymph Nodes:** provide lymph node status
   a. [Not performed]
   b. [Negative: 0 / <PROVIDE TOTAL LYMPH NODES>]
      a. [Positive: <PROVIDE TOTAL NUMBER OF POSITIVE LYMPH NODES> / <PROVIDE TOTAL LYMPH NODES> ; <LIST SIZE OF LARGEST LYMPH NODE METASTASIS AND IF THERE IS EXTRANODAL EXTENSION>]

14. **Cytology:** state whether or not cytology was performed and results, include accession number
   a. [Not performed]
   b. [Performed]:
      i. [Positive, <PROVIDE ACCESSION NUMBER IF AVAILABLE>]
      ii. [Negative, <PROVIDE ACCESSION NUMBER IF AVAILABLE>]

15. **Hormone Receptor Expression (by immunohistochemistry):** provide ER and PR expression if applicable
   a. [PENDING]
   b. [ER: POSITIVE; <PROVIDE PERCENTAGE OF TUMOR CELLS STAINING AND STRENGTH OF STAINING>]
   c. [ER: NEGATIVE]
   d. [PR: POSITIVE; <PROVIDE PERCENTAGE OF TUMOR CELLS STAINING AND STRENGTH OF STAINING>]
   e. [PR: NEGATIVE]

16. **Mismatch Repair (MMR) Protein Expression (by immunohistochemistry):** provide MMR status if performed
   a. [Not performed]
   b. [<INPUT WHETHER STAINS ARE INTACT OR THERE IS LOSS OF EXPRESSION HOWEVER YOU WANT>]

17. **Pathologic Staging:** may use AJCC and/or FIGO; refer to staging manuals